FCX
20
-6
BAX
32
-9
PNR
39
-8
TGT
34
-4
HON
44
-4
NUE
27
-6
AMZN
45
-5
BSX
56
-7
AVY
43
-4
HSIC
37
-8
SEE
18
-7
ALL
58
-2
MOS
26
-3
ECL
29
-6
MCD
52
5
EMN
45
-7
COF
50
-10
AMG
50
-5
CNX
37
-4
CMI
39
-7
FCX
20
-6
BAX
32
-9
PNR
39
-8
TGT
34
-4
HON
44
-4
NUE
27
-6
AMZN
45
-5
BSX
56
-7
AVY
43
-4
HSIC
37
-8
SEE
18
-7
ALL
58
-2
MOS
26
-3
ECL
29
-6
MCD
52
5
EMN
45
-7
COF
50
-10
AMG
50
-5
CNX
37
-4
CMI
39
-7
Financhill
Back

Fortress Biotech 10K Form

Sell
11

FBIO
Fortress Biotech

Last Price:
$1.42
Seasonality Move:
-13.11%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive FBIO News And Ratings

See the #1 stock for the next 7 days that we like better than FBIO

FBIO Financial Statistics

Sales & Book Value

Annual Sales: $57.7M
Cash Flow: $-20.1M
Price / Cash Flow: 0
Annual Sales: $0.77
Price / Book: 1.83

Profitability

EPS (TTM): -13.27000
Net Income (TTM): $-48.5M
Gross Margin: $36.8M
Return on Equity: 0%
Return on Assets: -32.11%

Fortress Biotech Earnings Forecast

Key Fortress Biotech Financial Ratios

  • The Gross Profit Margin over the past 11 years for FBIO is 63.80%.
  • The Selling, General & Administrative Expenses for FBIO have been equal to 152.11% of Gross Profit Margin.
  • The Research & Development expenses have been 98.62% of Revenue.
  • The Net Earning history of FBIO is -79.75% of Total Revenues.
  • Per Share Earnings over the last 15 years have been positive in 7 years.

Fortress Biotech Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: FBIO
CUSIP: 34960Q
Website: fortressbiotech.com

Debt

Debt-to-Equity Ratio: 2.54
Current Ratio: 1.23
Quick Ratio: 0.99

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 6.7

FBIO Technical Analysis vs Fundamental Analysis

Sell
11
Fortress Biotech (FBIO) is a Sell

Is Fortress Biotech a Buy or a Sell?

  • Fortress Biotech stock is rated a Sell
    The current Fortress Biotech [FBIO] share price is $1.41. The Score for FBIO is 11, which is 78% below its historic median score of 50, and infers higher risk than normal.